A New 1,2,3-Triazole Scaffold with Improved Potency against Staphylococcus aureus Biotin Protein Ligase
Staphylococcus aureus, a key ESKAPE bacteria, is responsible for most blood-based infections and, as a result, is a major economic healthcare burden requiring urgent attention. Here, we report in silico docking, synthesis, and assay of N1-diphenylmethyl triazole-based analogues (7–13) designed to in...
Gespeichert in:
Veröffentlicht in: | ACS infectious diseases 2022-12, Vol.8 (12), p.2579-2585 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2585 |
---|---|
container_issue | 12 |
container_start_page | 2579 |
container_title | ACS infectious diseases |
container_volume | 8 |
creator | Stachura, Damian L. Nguyen, Stephanie Polyak, Steven W. Jovcevski, Blagojce Bruning, John B. Abell, Andrew D. |
description | Staphylococcus aureus, a key ESKAPE bacteria, is responsible for most blood-based infections and, as a result, is a major economic healthcare burden requiring urgent attention. Here, we report in silico docking, synthesis, and assay of N1-diphenylmethyl triazole-based analogues (7–13) designed to interact with the entire binding site of S. aureus biotin protein ligase (SaBPL), an enzyme critical for the regulation of gluconeogenesis and fatty acid biosynthesis. The second aryl ring of these compounds enhances both SaBPL potency and whole cell activity against S. aureus relative to previously reported mono-benzyl triazoles. Analogues 12 and 13, with added substituents to better interact with the adenine binding site, are particularly potent, with K i values of 6.01 ± 1.01 and 8.43 ± 0.73 nM, respectively. These analogues are the most active triazole-based inhibitors reported to date and, importantly, inhibit the growth of a clinical isolate strain of S. aureus ATCC 49775, with minimum inhibitory concentrations of 1 and 8 μg/mL, respectively. |
doi_str_mv | 10.1021/acsinfecdis.2c00452 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2738194018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2738194018</sourcerecordid><originalsourceid>FETCH-LOGICAL-a275t-4f3d8a75f4ae75eea4ea2bd042223e04cae84efa7ed8eabdc82c120dfcb1ce993</originalsourceid><addsrcrecordid>eNp9kEtPwzAQhC0EAgT9BUjIRw4N-BWSHAviJVVQqeUcbe11MUrjYieg8usxakGcOM0evpndHUJOODvnTPAL0NG1FrVx8VxoxlQudsihkIXMSiGK3T_zARnE-MoY47LMlcr3yYG8lFXFZH5IFiP6iB-UD8VQZrPg4NM3SKcarPWNoR-ue6EPy1Xw72joxHfY6jWFBbg2dnTawepl3Xjtte4jhT5gkivnO9fSSUh00rFbQMRjsmehiTjY6hF5vr2ZXd9n46e7h-vROANR5F2mrDQlFLlVgEWOCApBzA1TQgiJTGnAUqGFAk2JMDe6FJoLZqyec41VJY_I2SY3nfzWY-zqpYsamwZa9H2sRSFLXinGy4TKDaqDjzGgrVfBLSGsa87q75LrPyXX25KT63S7oJ8v0fx6fipNwMUGSO761fehTf_-G_kFMpKMog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2738194018</pqid></control><display><type>article</type><title>A New 1,2,3-Triazole Scaffold with Improved Potency against Staphylococcus aureus Biotin Protein Ligase</title><source>ACS Publications</source><source>MEDLINE</source><creator>Stachura, Damian L. ; Nguyen, Stephanie ; Polyak, Steven W. ; Jovcevski, Blagojce ; Bruning, John B. ; Abell, Andrew D.</creator><creatorcontrib>Stachura, Damian L. ; Nguyen, Stephanie ; Polyak, Steven W. ; Jovcevski, Blagojce ; Bruning, John B. ; Abell, Andrew D.</creatorcontrib><description>Staphylococcus aureus, a key ESKAPE bacteria, is responsible for most blood-based infections and, as a result, is a major economic healthcare burden requiring urgent attention. Here, we report in silico docking, synthesis, and assay of N1-diphenylmethyl triazole-based analogues (7–13) designed to interact with the entire binding site of S. aureus biotin protein ligase (SaBPL), an enzyme critical for the regulation of gluconeogenesis and fatty acid biosynthesis. The second aryl ring of these compounds enhances both SaBPL potency and whole cell activity against S. aureus relative to previously reported mono-benzyl triazoles. Analogues 12 and 13, with added substituents to better interact with the adenine binding site, are particularly potent, with K i values of 6.01 ± 1.01 and 8.43 ± 0.73 nM, respectively. These analogues are the most active triazole-based inhibitors reported to date and, importantly, inhibit the growth of a clinical isolate strain of S. aureus ATCC 49775, with minimum inhibitory concentrations of 1 and 8 μg/mL, respectively.</description><identifier>ISSN: 2373-8227</identifier><identifier>EISSN: 2373-8227</identifier><identifier>DOI: 10.1021/acsinfecdis.2c00452</identifier><identifier>PMID: 36399035</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - pharmacology ; Bacterial Proteins - antagonists & inhibitors ; Biotin ; Carbon-Nitrogen Lyases - antagonists & inhibitors ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - enzymology ; Triazoles - chemistry ; Triazoles - pharmacology</subject><ispartof>ACS infectious diseases, 2022-12, Vol.8 (12), p.2579-2585</ispartof><rights>2022 American Chemical Society</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a275t-4f3d8a75f4ae75eea4ea2bd042223e04cae84efa7ed8eabdc82c120dfcb1ce993</citedby><cites>FETCH-LOGICAL-a275t-4f3d8a75f4ae75eea4ea2bd042223e04cae84efa7ed8eabdc82c120dfcb1ce993</cites><orcidid>0000-0002-0604-2629 ; 0000-0002-4895-1062 ; 0000-0002-6919-1824 ; 0000-0001-7999-1385</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.2c00452$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsinfecdis.2c00452$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36399035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stachura, Damian L.</creatorcontrib><creatorcontrib>Nguyen, Stephanie</creatorcontrib><creatorcontrib>Polyak, Steven W.</creatorcontrib><creatorcontrib>Jovcevski, Blagojce</creatorcontrib><creatorcontrib>Bruning, John B.</creatorcontrib><creatorcontrib>Abell, Andrew D.</creatorcontrib><title>A New 1,2,3-Triazole Scaffold with Improved Potency against Staphylococcus aureus Biotin Protein Ligase</title><title>ACS infectious diseases</title><addtitle>ACS Infect. Dis</addtitle><description>Staphylococcus aureus, a key ESKAPE bacteria, is responsible for most blood-based infections and, as a result, is a major economic healthcare burden requiring urgent attention. Here, we report in silico docking, synthesis, and assay of N1-diphenylmethyl triazole-based analogues (7–13) designed to interact with the entire binding site of S. aureus biotin protein ligase (SaBPL), an enzyme critical for the regulation of gluconeogenesis and fatty acid biosynthesis. The second aryl ring of these compounds enhances both SaBPL potency and whole cell activity against S. aureus relative to previously reported mono-benzyl triazoles. Analogues 12 and 13, with added substituents to better interact with the adenine binding site, are particularly potent, with K i values of 6.01 ± 1.01 and 8.43 ± 0.73 nM, respectively. These analogues are the most active triazole-based inhibitors reported to date and, importantly, inhibit the growth of a clinical isolate strain of S. aureus ATCC 49775, with minimum inhibitory concentrations of 1 and 8 μg/mL, respectively.</description><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacterial Proteins - antagonists & inhibitors</subject><subject>Biotin</subject><subject>Carbon-Nitrogen Lyases - antagonists & inhibitors</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - enzymology</subject><subject>Triazoles - chemistry</subject><subject>Triazoles - pharmacology</subject><issn>2373-8227</issn><issn>2373-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtPwzAQhC0EAgT9BUjIRw4N-BWSHAviJVVQqeUcbe11MUrjYieg8usxakGcOM0evpndHUJOODvnTPAL0NG1FrVx8VxoxlQudsihkIXMSiGK3T_zARnE-MoY47LMlcr3yYG8lFXFZH5IFiP6iB-UD8VQZrPg4NM3SKcarPWNoR-ue6EPy1Xw72joxHfY6jWFBbg2dnTawepl3Xjtte4jhT5gkivnO9fSSUh00rFbQMRjsmehiTjY6hF5vr2ZXd9n46e7h-vROANR5F2mrDQlFLlVgEWOCApBzA1TQgiJTGnAUqGFAk2JMDe6FJoLZqyec41VJY_I2SY3nfzWY-zqpYsamwZa9H2sRSFLXinGy4TKDaqDjzGgrVfBLSGsa87q75LrPyXX25KT63S7oJ8v0fx6fipNwMUGSO761fehTf_-G_kFMpKMog</recordid><startdate>20221209</startdate><enddate>20221209</enddate><creator>Stachura, Damian L.</creator><creator>Nguyen, Stephanie</creator><creator>Polyak, Steven W.</creator><creator>Jovcevski, Blagojce</creator><creator>Bruning, John B.</creator><creator>Abell, Andrew D.</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0604-2629</orcidid><orcidid>https://orcid.org/0000-0002-4895-1062</orcidid><orcidid>https://orcid.org/0000-0002-6919-1824</orcidid><orcidid>https://orcid.org/0000-0001-7999-1385</orcidid></search><sort><creationdate>20221209</creationdate><title>A New 1,2,3-Triazole Scaffold with Improved Potency against Staphylococcus aureus Biotin Protein Ligase</title><author>Stachura, Damian L. ; Nguyen, Stephanie ; Polyak, Steven W. ; Jovcevski, Blagojce ; Bruning, John B. ; Abell, Andrew D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a275t-4f3d8a75f4ae75eea4ea2bd042223e04cae84efa7ed8eabdc82c120dfcb1ce993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacterial Proteins - antagonists & inhibitors</topic><topic>Biotin</topic><topic>Carbon-Nitrogen Lyases - antagonists & inhibitors</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - enzymology</topic><topic>Triazoles - chemistry</topic><topic>Triazoles - pharmacology</topic><toplevel>online_resources</toplevel><creatorcontrib>Stachura, Damian L.</creatorcontrib><creatorcontrib>Nguyen, Stephanie</creatorcontrib><creatorcontrib>Polyak, Steven W.</creatorcontrib><creatorcontrib>Jovcevski, Blagojce</creatorcontrib><creatorcontrib>Bruning, John B.</creatorcontrib><creatorcontrib>Abell, Andrew D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>ACS infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stachura, Damian L.</au><au>Nguyen, Stephanie</au><au>Polyak, Steven W.</au><au>Jovcevski, Blagojce</au><au>Bruning, John B.</au><au>Abell, Andrew D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A New 1,2,3-Triazole Scaffold with Improved Potency against Staphylococcus aureus Biotin Protein Ligase</atitle><jtitle>ACS infectious diseases</jtitle><addtitle>ACS Infect. Dis</addtitle><date>2022-12-09</date><risdate>2022</risdate><volume>8</volume><issue>12</issue><spage>2579</spage><epage>2585</epage><pages>2579-2585</pages><issn>2373-8227</issn><eissn>2373-8227</eissn><abstract>Staphylococcus aureus, a key ESKAPE bacteria, is responsible for most blood-based infections and, as a result, is a major economic healthcare burden requiring urgent attention. Here, we report in silico docking, synthesis, and assay of N1-diphenylmethyl triazole-based analogues (7–13) designed to interact with the entire binding site of S. aureus biotin protein ligase (SaBPL), an enzyme critical for the regulation of gluconeogenesis and fatty acid biosynthesis. The second aryl ring of these compounds enhances both SaBPL potency and whole cell activity against S. aureus relative to previously reported mono-benzyl triazoles. Analogues 12 and 13, with added substituents to better interact with the adenine binding site, are particularly potent, with K i values of 6.01 ± 1.01 and 8.43 ± 0.73 nM, respectively. These analogues are the most active triazole-based inhibitors reported to date and, importantly, inhibit the growth of a clinical isolate strain of S. aureus ATCC 49775, with minimum inhibitory concentrations of 1 and 8 μg/mL, respectively.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>36399035</pmid><doi>10.1021/acsinfecdis.2c00452</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0604-2629</orcidid><orcidid>https://orcid.org/0000-0002-4895-1062</orcidid><orcidid>https://orcid.org/0000-0002-6919-1824</orcidid><orcidid>https://orcid.org/0000-0001-7999-1385</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2373-8227 |
ispartof | ACS infectious diseases, 2022-12, Vol.8 (12), p.2579-2585 |
issn | 2373-8227 2373-8227 |
language | eng |
recordid | cdi_proquest_miscellaneous_2738194018 |
source | ACS Publications; MEDLINE |
subjects | Anti-Bacterial Agents - chemistry Anti-Bacterial Agents - pharmacology Bacterial Proteins - antagonists & inhibitors Biotin Carbon-Nitrogen Lyases - antagonists & inhibitors Staphylococcus aureus - drug effects Staphylococcus aureus - enzymology Triazoles - chemistry Triazoles - pharmacology |
title | A New 1,2,3-Triazole Scaffold with Improved Potency against Staphylococcus aureus Biotin Protein Ligase |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T15%3A56%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20New%201,2,3-Triazole%20Scaffold%20with%20Improved%20Potency%20against%20Staphylococcus%20aureus%20Biotin%20Protein%20Ligase&rft.jtitle=ACS%20infectious%20diseases&rft.au=Stachura,%20Damian%20L.&rft.date=2022-12-09&rft.volume=8&rft.issue=12&rft.spage=2579&rft.epage=2585&rft.pages=2579-2585&rft.issn=2373-8227&rft.eissn=2373-8227&rft_id=info:doi/10.1021/acsinfecdis.2c00452&rft_dat=%3Cproquest_cross%3E2738194018%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2738194018&rft_id=info:pmid/36399035&rfr_iscdi=true |